William Tang Email

Director Finance . Arrakis Therapeutics

Current Roles

Employees:
119
Revenue:
$23.9M
About
Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. The company's TRYST and PEARL-seq platforms identify new RNA targets and drug candidates to treat diseases unaddressed by today's medicines. Arrakis is developing a proprietary pipeline of RNA-targeted small molecules focused on neurologic diseases, cancer, and rare genetic diseases. Arrakis was founded in 2015 by Russell Petter, Ph.D., Alan Walts, Ph.D., Henri Termeer and Raj Parekh, Ph.D. with a vision to create a proprietary, transformational discovery platform that identifies small-molecule drugs that act directly on disease-causing RNA. The company was established with seed funding provided by Advent Life Sciences and Henri Termeer. The company brings together scientific leaders in RNA structure, chemistry and biology, along with a highly experienced management team and the backing of leading life sciences investors. The company is located in Waltham, Mass.
Arrakis Therapeutics Address
828 Winter Street
Waltham, MA
United States
Arrakis Therapeutics Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.